Note: This document contains side effect information about lisinopril. Some dosage forms listed on this page may not apply to the brand name Qbrelis.

Summary

Common side effects of Qbrelis include: hypotension. Other side effects include: hyperkalemia. Continue reading for a comprehensive list of adverse effects.

Applies to lisinopril: oral extemporaneous suspension, oral tablets.

Side effects include:

Patients with hypertension: Headache, dizziness, cough, fatigue, diarrhea, upper respiratory tract infection, nausea. With fixed combination preparation, muscle cramps, asthenia, orthostatic effects, paresthesia.

Patients with heart failure: Dizziness, hypotension, headache, diarrhea, chest pain, nausea, abdominal pain, rash, upper respiratory tract infection.

Patients with acute MI: Hypotension, renal dysfunction.

For Healthcare Professionals

Applies to lisinopril: oral solution, oral tablet.

Cardiovascular

Very common (10% or more): Hypotension (11%)

Common (1% to 10%): Chest pain, angina pectoris, orthostatic hypotension, palpitations

Uncommon (0.1% to 1%): Angioneurotic edema, myocardial infarction or cerebrovascular accident, palpitations, tachycardia, Raynaud's phenomenon^[Ref]

Hypotension is most likely in patients who are sodium and intravascular volume depleted. In large studies, patients have reported "heart pounding" and chest pain, although the relationship to lisinopril is questionable.^[Ref]

Renal

Common (1% to 10%): Creatinine increased (10%)

Very rare (less than 0.01%): Renal insufficiency^[Ref]

Nervous system

Very common (10% or more): Dizziness (19%)

Common (1% to 10%): Headache, syncope

Uncommon (0.1% to 1%): Paresthesias^[Ref]

Respiratory

Common (1% to 10%): Creatinine increased (10%)

Uncommon (0.1% to 1%): Rhinitis

Very rare (less than 0.01%): Bronchospasm, sinusitis, allergic alveolitis/eosinophilic pneumonia^[Ref]

A study has revealed a significantly higher incidence of discontinuation of angiotensin converting enzyme inhibitor therapy due to cough among black patients compared with nonblack patients (9.6% vs. 2.4%).^[Ref]

Metabolic

Common (1% to 10%): Hyperkalemia

Frequency not reported: Gout, hypoglycemia in diabetic patients receiving ACE inhibitors when concurrently treated with oral antidiabetic agents or insulin^[Ref]

Gastrointestinal

Common (1% to 10%): Diarrhea, nausea, vomiting

Frequency not reported: Pancreatitis, constipation, flatulence, dry mouth, taste disturbance^[Ref]

Hypersensitivity

Uncommon (0.1% to 1%): Angioedema^[Ref]

Dermatologic

Uncommon (0.1% to 1%): Rash, pruritus, erythema

Rare (0.01% to 0.1%): Alopecia, urticaria, psoriasis, hypersensitivity/angioedema, angioneurotic edema of the face, extremities, lips, tongue, glottis, and/or larynx

Very rare (less than 0.01%): Sweating, skin lesions, skin infections, pemphigus, toxic epidermal necrolysis, Stevens-Johnson Syndrome, erythema multiforme, cutaneous pseudolymphoma

Frequency not reported: Photosensitivity, flushing, diaphoresis^[Ref]

Hematologic

Very rare (less than 0.01%): Bone marrow depression, hemolytic anemia, leukopenia/neutropenia, thrombocytopenia, decreases in hemoglobin, decreases in hematocrit^[Ref]

Psychiatric

Rare (0.01% to 0.1%): Memory impairment, confusion, somnolence, irritability, nervousness, hallucinations

Very rare (less than 0.01%): Mania

Hepatic

Common (1% to 10%): Creatinine increased

Very rare (less than 0.01%): Cholestatic jaundice that progresses to fulminant hepatic necrosis and sometimes death (discontinue of therapy if jaundice or markedly elevated hepatic serum enzymes develop)

Endocrine

Very rare (less than 0.01%): Diabetes, syndrome of inappropriate antidiuretic hormone secretion (SIADH)

Other

Common (1% to 10%): Cough

Frequency not reported: Fatigue, asthenia, orthostatic effects, tinnitus, olfactory disturbance

Genitourinary

Uncommon (0.1% to 1%): Impotence

Rare (less than 0.1%): Gynecomastia

Frequency not reported: Proteinuria